Merck (NYSE:MRK) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for gefapixant, a non-narcotic oral selective P2X3 receptor antagonist developed for the treatment of adults with chronic cough. The recommendation will be reviewed by the European Commission for marketing authorization in the EU, with a final decision expected later this year.